|

EXELIXIS INC (EXEL)

US30161Q1040 - Common Stock

22  +0.01 (+0.05%)

After market: 22 0 (0%)

News Image
11 days ago - FinancialNewsMedia

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

News Image
11 days ago - USA News Group

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

/PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this...

News Image
11 days ago - Chartmill

NASDAQ:EXEL, a growth stock which is not overvalued.

Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.

News Image
17 days ago - Chartmill

Will EXELIXIS INC Break Out? A Technical Analysis Perspective.

Will EXELIXIS INC breakout?

News Image
a month ago - InvestorPlace

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

News Image
a month ago - InvestorPlace

3 Biotech Stocks With the Strongest Clinical Pipelines

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

News Image
a month ago - InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

News Image
a month ago - The Motley Fool

Exelixis (EXEL) Q3 2023 Earnings Call Transcript

EXEL earnings call for the period ending September 30, 2023.

News Image
a month ago - The Motley Fool

4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.

News Image
2 months ago - FinancialNewsMedia

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

News Image
2 months ago - FinancialNewsMedia.com

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

/PRNewswire/ -- The R&D for cancer vaccines has been growing in the last few years and is projected to continue through the next decade. A cancer vaccine is...

News Image
2 months ago - Seeking Alpha

Exelixis reports positive results for Cabometyx in treating neuroendocrine tumors

Exelixis (EXEL) reported positive Phase 3 results for its drug Cabometyx in the treatment of certain neuroendocrine tumors. Read more here.

News Image
2 months ago - Market News Video

Oversold Conditions For Exelixis (EXEL)

News Image
2 months ago - The Motley Fool

3 Under-the-Radar Biotech Stocks to Buy in 2023

These three lesser-known biotech companies are profitable and growing revenue.

News Image
2 months ago - The Motley Fool

Is Exelixis Stock a Buy Now?

There is one key reason to consider the stock.

News Image
2 months ago - InvestorPlace

Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains

Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.

News Image
2 months ago - Seeking Alpha

Exelixis started at buy at Wainwright on targeted oncology pipeline (NASDAQ:EXEL)

H.C. Wainwright initiates Exelixis with a buy rating, citing its robust pipeline of targeted oncology assets. Read more here.

News Image
3 months ago - InvestorPlace

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall

Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.

News Image
3 months ago - The Motley Fool

4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

A 14% decline in the Nasdaq Composite represents the perfect opportunity for investors to pounce.